InvestorsHub Logo
Followers 48
Posts 9781
Boards Moderated 1
Alias Born 01/31/2008

Re: nidan7500 post# 359823

Tuesday, 05/10/2022 2:08:14 PM

Tuesday, May 10, 2022 2:08:14 PM

Post# of 462017
HUGELY Disappointing:

Meeting with FDA for discussing ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study. WhyTF hasn't this occurred already They have had the results for what, 2 year now?

Planned initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical study. WhyTF hasn't this occurred already

Planned initiation of a potentially pivotal Phase 2/3 study in Fragile X Syndrome, the most frequent genetic cause of autism spectrum disorder. WhyTF hasn't this occurred already They have had more than two years to prepare this.

Planned initiation of a Phase 2/3 clinical trial for the treatment of a new rare-disease indication. WhyTF hasn't this occurred already Enough of the tease. They have had more than two years to prepare this.

Planned initiation of ANAVEX®3-71 Phase 2 clinical trials for FTD, schizophrenias and Alzheimer’s disease indications. OK, get it started.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News